This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Towards Reducing Resistance and Hematological Toxicity of Linezolid

This study has been completed.
Monash University
Information provided by:
University of Pittsburgh Identifier:
First received: September 13, 2005
Last updated: December 16, 2008
Last verified: December 2008
The study will evaluate and improve the performance of pharmaco-statistical models previously developed in the compassionate use program in patients being treated with linezolid under clinical usage conditions. This study will also develop a sensitive and specific tool that may be used to predict patients at risk of hematological toxicity, based on factors including linezolid concentration and duration of therapy and use these models to better understand the determinants of toxicity with linezolid and define better strategies to manage toxicity or reduce its occurrence.

Condition Phase
Infection Adverse Effects Phase 4

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Towards Reducing Resistance and Hematological Toxicity of Linezolid

Resource links provided by NLM:

Further study details as provided by University of Pittsburgh:

Estimated Enrollment: 50
Study Start Date: August 2005
Study Completion Date: February 2007
  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males or females greater than 18 years of age.
  • All patients will remain in the hospital for pharmacokinetic sampling.
  • All subjects must be on the medication linezolid as part of their standard of care.

Exclusion Criteria:

  • Patients with renal failure who receive peritoneal dialysis, hemodialysis or hemofiltration.
  • Any contraindication to blood sampling
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00177723

United States, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
University of Pittsburgh
Monash University
Principal Investigator: David L Paterson, MD University of Pittsburgh
  More Information Identifier: NCT00177723     History of Changes
Other Study ID Numbers: IRB# 0501019
Study First Received: September 13, 2005
Last Updated: December 16, 2008

Keywords provided by University of Pittsburgh:
receiving antibiotic Linezolid clinically

Additional relevant MeSH terms:
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on August 21, 2017